Abstract:This study examines the role of new genome editing tools in treating retinitis pigmentosa (RP), particularly focusing on the Pde6a‐D670G mutation. Highlighting the potential of engineered base editing (BE) and prime editing (PE), it demonstrates how these advanced techniques can precisely correct the point mutation in Pde6a mouse model, effectively restoring retinal function. Retinitis pigmentosa (RP) is a complex spectrum of inherited retinal diseases marked by the gradual loss of photoreceptor cells, ultimately leading to blindness. Among these, mutations in PDE6A, responsible for encoding a cGMP‐specific phosphodiesterase, stand out as pivotal in autosomal recessive RP (RP43). Unfortunately, no effective therapy currently exists for this specific form of RP. However, recent advancements in genome editing, such as base editing (BE) and prime editing (PE), offer a promising avenue for precise and efficient gene therapy. Here, it is illustrated that the engineered BE and PE systems, particularly PE, exhibit high efficiency in rescuing a target point mutation with minimal bystander effects in an RP mouse model carrying the Pde6a (c.2009A > G, p.D670G) mutation. The optimized BE and PE systems are first screened in N2a cells and subsequently assessed in electroporated mouse retinas. Notably, the optimal PE system, delivered via dual adeno‐associated virus (AAV), precisely corrects the pathogenic mutation with average 9.4% efficiency, with no detectable bystander editing. This correction restores PDE6A protein expression, preserved photoreceptors, and rescued retinal function in Pde6a mice. Therefore, this study offers a proof‐of‐concept demonstration for the treatment of Pde6a‐related retinal degeneration using BE and PE systems.

Vision Rescue Via Unconstrained in Vivo Prime Editing in Degenerating Neural Retinas

Efficient Rescue of Retinal Degeneration in Pde6a Mice by Engineered Base Editing and Prime Editing

In vivo base editing rescues photoreceptors in a mouse model of retinitis pigmentosa

In Vivo CRISPR/Cas9-Mediated Genome Editing Mitigates Photoreceptor Degeneration in a Mouse Model of X-Linked Retinitis Pigmentosa

AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa

Restoration of RPGR expression in vivo using CRISPR/Cas9 gene editing

All-in-one AAV-mediated Nrl gene inactivation rescues retinal degeneration in Pde6a mice

Gene Editing Preserves Visual Functions in a Mouse Model of Retinal Degeneration

CRISPR editing of anti-anemia drug target rescues independent preclinical models of retinitis pigmentosa

Allele-specific CRISPR/Cas9 genome editing of the single-base P23H mutation for rhodopsin associated dominant retinitis pigmentosa

Systematic Evaluation Of A Targeted Gene Capture Sequencing Panel For Molecular Diagnosis Of Retinitis Pigmentosa

Gene Correction Reverses Ciliopathy and Photoreceptor Loss in Ipsc-Derived Retinal Organoids from Retinitis Pigmentosa Patients

CRISPR/SaCas9-based gene editing rescues photoreceptor degeneration throughout a rhodopsin-associated autosomal dominant retinitis pigmentosa mouse model

Identification of RPGR ORF15 mutation for X-linked retinitis pigmentosa in a large Chinese family and in vitro correction with prime editor

Visual function restoration in genetically blind mice via endogenous cellular reprogramming

Toward genome editing in X-linked RP-development of a mouse model with specific treatment relevant features

In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa

In vivo base editing rescues cone photoreceptors in a mouse model of early-onset inherited retinal degeneration

Gene augmentation prevents retinal degeneration in a CRISPR/Cas9-based mouse model of PRPF31 retinitis pigmentosa

Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration

Treatment of autosomal dominant retinitis pigmentosa caused by RHO-P23H mutation with high-fidelity Cas13X in mice